


International Application Publication WO 01/47905 discloses certain pyrrolidine derivative compounds as inhibitors of phosphodiesterase, in particular, PDE4, and recites the compounds as useful in treating a number of diseases including asthma.

Summary

In one aspect, there is provided a compound of the formula



or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or methyl.

In another aspect, there is provided a pharmaceutical composition comprising a compound as disclosed above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

~~In another aspect, there is provided a pharmaceutical composition comprising a first component which is a compound as disclosed above, or a pharmaceutically acceptable salt thereof, and a second component which is tadalafil, and a pharmaceutically acceptable carrier, diluent or excipient~~

In another aspect, there is provided a use of a compound as disclosed above, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of overactive bladder.


~~In another aspect, there is provided use of a compound as disclosed above, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of overactive bladder, wherein said compound is to be administered in combination with tadalafil.~~

In another aspect, there is provided a compound as disclosed above, or a pharmaceutically acceptable salt thereof, for use in therapy.

In another aspect, there is provided a compound as disclosed above, or a pharmaceutically acceptable salt thereof, for use in the treatment of overactive bladder.


We claim:

1. A compound of the formula



or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or methyl.

2. The compound or salt of claim 1 of the formula



wherein R is hydrogen or methyl.

3. The compound or salt of claim 1 or 2 wherein R is methyl.
4. The compound of claim 1, wherein the compound which is (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol.
5. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
6. TheA pharmaceutical composition of claim 5, comprising a first component which is a compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, and a second component which is tadalafil, and a pharmaceutically acceptable carrier, diluent or excipient.

7. Use of a compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of overactive bladder.
8. ~~The Use according to claim 7 of a compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of overactive bladder,~~ wherein said compound is to be administered in combination with tadalafil.
9. The use of claim 8, wherein the compound is (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-[[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol, or a pharmaceutically acceptable salt thereof, in combination with tadalafil.
10. A compound as claimed in any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, for use in therapy.
11. A compound as claimed in any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, for use in the treatment of overactive bladder.